Neuroendocrine tumor cells in prostate cancer: Evaluation of the neurosecretory products serotonin, bombesin, and gastrin - Impact on angiogenesis and clinical follow-up

Prostate

Volumn 71, Issue 16, 2011, Pages 1752-1758

  Heinrich, Elmar ^a   Trojan, Lutz ^a   Friedrich, Dorothee ^a   Voß, Martin ^a   Weiss, Christel ^a   Michel, Maurice Stephan ^a   Grobholz, Rainer ^b  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b CANTONAL HOSPITAL AARAU   (Switzerland)

Author keywords

angiogenesis; bombesin; gastrin; neuroendocrine differentiation; prostatic neoplasm; serotonin

Indexed keywords

BOMBESIN; CD34 ANTIGEN; CHROMOGRANIN A; GASTRIN; SEROTONIN;

ADULT; AGED; ANGIOGENESIS; ARTICLE; CELLULAR DISTRIBUTION; FOLLOW UP; GENERAL PATHOLOGICAL PARAMETERS; GLEASON SCORE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; MICROVASCULATURE; MICROVESSEL DENSITY; NEUROENDOCRINE DIFFERENTIATED TUMOR CELL; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROTEIN EXPRESSION; TREATMENT FAILURE; TUMOR CELL;

AGED; BOMBESIN; CARCINOMA, NEUROENDOCRINE; CELL DIFFERENTIATION; FOLLOW-UP STUDIES; GASTRINS; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; NEOVASCULARIZATION, PATHOLOGIC; PROSTATE; PROSTATIC NEOPLASMS; RISK FACTORS; SEROTONIN; TUMOR MARKERS, BIOLOGICAL;

EID: 80054085813     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.21392     Document Type: Article

References (24)

1. Grobholz R, Bohrer MH, Siegsmund M, Junemann KP, Bleyl U, Woenckhaus M,. Correlation between neovascularisation and neuroendocrine differentiation in prostatic carcinoma. Pathol Res Pract 2000; 196: 277-284. (Pubitemid 30313232)
2. di Sant'Agnese PA,. Neuroendocrine differentiation in prostatic carcinoma: An update. Prostate Suppl 1998; 8: 74-79. (Pubitemid 28347998)
3. Abrahamsson PA, Cockett AT, di Sant'Agnese PA,. Prognostic significance of neuroendocrine differentiation in clinically localized prostatic carcinoma. Prostate Suppl 1998; 8: 37-42. (Pubitemid 28347994)
4. Bostwick DG, Qian J, Pacelli A, Zincke H, Blute M, Bergstralh EJ, Sleazak JM, Cheng L,. Neuroendocrine expression in node positive prostate cancer: Correlation with systemic progression and patient survival. J Urol 2002; 168: 1204-1211.
5. Grobholz R, Griebe M, Sauer CG, Michel MS, Trojan L, Bleyl U,. Influence of neuroendocrine tumor cells on proliferation in prostatic carcinoma. Hum Pathol 2005; 36: 562-570. (Pubitemid 40776010)
6. Weinstein MH, Partin AW, Veltri RW, Epstein JI,. Neuroendocrine differentiation in prostate cancer: Enhanced prediction of progression after radical prostatectomy. Hum Pathol 1996; 27: 683-687. (Pubitemid 26240320)
7. Feldman SA, Eiden LE,. The chromogranins. Their roles in secretion from neuroendocrine cells and as markers for neuroendocrine neoplasia. Endocr Pathol 2003; 14: 3-23. (Pubitemid 36605679)
8. Seuwen K, Pouyssegur J,. Serotonin as a growth factor. Biochem Pharmacol 1990; 39: 985-990. (Pubitemid 20103670)
9. Mahmoud S, Staley J, Taylor J, Bodgen A, Moreau JP, Coy D, Avis I, Cuttitta F, Mulshine JL, Moody TW,. [Psi 13,14] bombesin analogues inhibit growth of small cell lung cancer in vitro and in vivo. Cancer Res 1991; 51: 1798-1802.
10. Bonkhoff H, Wernert N, Dhom G, Remberger K,. Relation of endocrine-paracrine cells to cell proliferation in normal, hyperplastic, and neoplastic human prostate. Prostate 1991; 19: 91-98.
11. Sobin LH, Wittekind CH,. Urological tumors: Prostate. In:, Sobin LH, Wittekind CH, editors. TNM classification of malignant tumors. 6th edition. New Jersey: John Wiley & Sons, Hoboken; 2002.
12. Gleason DF, Mellinger GT, Veterans Administration Cooperative Urological Research Group. Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. J Urol 1973; 111: 58.
13. Ahlgren G, Pedersen K, Lundberg S, Aus G, Hugosson J, Abrahamsson PA,. Regressive changes and neuroendocrine differentiation in prostate cancer after neoadjuvant hormonal treatment. Prostate 2000; 42: 274-279. (Pubitemid 30104570)
14. Segawa N, Mori I, Utsunomiya H, Nakamura M, Nakamura Y, Shan L, Kakudo K, Katsuoka Y,. Prognostic significance of neuroendocrine differentiation, proliferation activity and androgen receptor expression in prostate cancer. Pathol Int 2001; 51: 452-459. (Pubitemid 32646211)
15. Huhnt W, Lubbe AS,. Growth, microvessel density and tumor cell invasion of human colon adenocarcinoma under repeated treatment with hyperthermia and serotonin. J Cancer Res Clin Oncol 1995; 121: 423-428.
16. Clarke PA, Dickson JH, Harris JC, Grabowska A, Watson SA,. Gastrin enhances the angiogenic potential of endothelial cells via modulation of heparin-binding epidermal-like growth factor. Cancer Res 2006; 66: 3504-3512.
17. Busby JE, Shih SJ, Yang JC, Kung HJ, Evans CP,. Angiogenesis is not mediated by prostate cancer neuropeptides. Angiogenesis 2003; 6: 289-293. (Pubitemid 38987538)
18. Borre M, Nerstrom B, Overgaard J,. Association between immunohistochemical expression of vascular endothelial growth factor (VEGF), VEGF-expressing neuroendocrine-differentiated tumor cells, and outcome in prostate cancer patients subjected to watchful waiting. Clin Cancer Res 2000; 6: 1882-1890. (Pubitemid 30305085)
19. Harper ME, Glynne-Jones E, Goddard L, Thurston VJ, Griffiths K,. Vascular endothelial growth factor (VEGF) expression in prostatic tumors and its relationship to neuroendocrine cells. Br J Cancer 1996; 74: 910-916. (Pubitemid 26319324)
20. Fischer-Colbrie R, Kirchmaier R, Kahler CM, Wiedermann CJ, Saria A,. Secretoneurin: A new player in angiogenesis and chemotaxis linking nerves, blood vessels and the immune system. Curr Protein Pept Sci 2005; 6: 373-385. (Pubitemid 41052403)
21. Albrecht M, Doroszewicz J, Gillen S, Gomez I, Wilhelm B, Stief T, Aumüller G,. Proliferation of prostate cancer cells and activity of neutral endopeptidase is regulated by bombesin and IL-1beta with IL-1beta acting as a modulator of cellular differentiation. Prostate 2004; 58: 82-94. (Pubitemid 38057992)
22. Xiao D, Chinnappan D, Pestell R, Albanese C, Weber HC,. Bombesin regulates cyclin D1 expression through the early growth response protein Egr-1 in prostate cancer cells. Cancer Res 2005; 65: 9934-9942. (Pubitemid 41541474)
23. Stangelberger A, Schally AV, Varga JL, Zarandi M, Cai RZ, Baker B, Hammann BD, Armatis P, Kanashiro CA,. Inhibition of human androgen-independent PC-3 and DU-145 prostate cancers by antagonists of bombesin and growth hormone releasing hormone is linked to PKC, MAPK and c-jun intracellular signalling. Eur J Cancer 2005; 41: 2735-2744. (Pubitemid 41607567)
24. Stangelberger A, Schally AV, Letsch M, Szepeshazi K, Nagy A, Halmos G, Kanashiro CA, Corey E, Vessella R,. Targeted chemotherapy with cytotoxic bombesin analogue AN-215 inhibits growth of experimental human prostate cancers. Int J Cancer 2006; 118: 222-229. (Pubitemid 41681603)